A systematic literature review identified two studies that met the inclusion criteria of patients with HAE aged <12 years receiving LTP: lanadelumab (SPRING, NCT04070326) and intravenous-C1-esterase inhibitor (2019 C1-INH study, NCT02052141). Here, C1S is linked to hereditary angioedema.